Related Experiment Video
Updated: Jun 1, 2026
07:04
A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats
Published on: August 19, 2018
Kynurenines and headache
Arpád Párdutz1, Annamária Fejes, Zsuzsanna Bohár
1Department of Neurology, Albert Szent-Györgyi Clinical Center, University of Szeged, Semmelweis u. 6, Szeged, 6725, Hungary. apardutz@yahoo.com
Summary
The kynurenine pathway influences migraine by affecting glutamate neurotransmission and trigeminal activation. Kynurenic acid shows neuroprotective potential, impacting migraine pathogenesis.
Area of Science:
- Neuroscience
- Biochemistry
- Pathophysiology
Background:
- The kynurenine pathway is a major metabolic route for tryptophan, producing neuroactive compounds.
- Kynurenic acid, a kynurenine metabolite, exhibits neuroprotective properties by inhibiting glutamate receptors.
- Glutamate plays a critical role in migraine, including cortical spreading depression and trigeminal system activation.
Purpose of the Study:
- To summarize current findings on the kynurenine system's role in migraine pathogenesis.
- To investigate the involvement of kynurenines in trigeminal activation and related migraine events.
Main Methods:
- Review of existing research on the kynurenine pathway and its metabolites.
- Analysis of the interplay between kynurenines, glutamate, and serotonin metabolism.
- Examination of kynurenine system's impact on trigeminal activation and migraine pathophysiology.
Main Results:
- Kynurenines, particularly kynurenic acid, modulate glutamatergic neurotransmission, a key factor in migraine.
- The kynurenine system may influence migraine directly through neuromodulatory effects and indirectly via serotonin metabolism.
- Evidence suggests a significant role for the kynurenine system in trigeminal activation during migraine.
Conclusions:
- The kynurenine pathway is implicated in migraine pathogenesis through its effects on glutamate and trigeminal activation.
- Kynurenic acid's neuroprotective actions highlight its potential relevance in migraine treatment strategies.
- Further research into the kynurenine system could offer new insights into migraine mechanisms and therapeutic targets.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...